Chief Executive Officer,

Tsukasa Sugo, Ph.D.

Tsukasa Sugo received B.S. in Chemistry from the University of Tokyo and Ph.D. degrees from Graduate School of Pharmaceutical Sciences, the University of Tokyo. After the researches in the Institute of Medical Science, the University of Tokyo, he worked at Takeda Pharmaceutical Company Limited for 25 years in G protein-coupled receptor research, nucleic acid pharmaceutical research and genome editing research. During his career in Takeda, he had an opportunity to work for Alnylam Pharmaceuticals as a visiting scientist. He was awarded as the Outstanding Reviewers status for Journal of Controlled Release.
Vise President
Chief Operating Officer,

Mie Yoshimatsu

Mie Yoshimatsu graduated from Kyoto Pharmaceutical University with a Bachelor of Pharmacy degree. She joined Takeda Pharmaceutical Company Limited and was in charge of a wide range of tasks including monoclonal antibody production, medical pharmacology (in vitro, in vivo), screening and molecular biology. She has track record of INDs including Relugolix, Resatorvid, etc.

Akihiro Tomoyasu, Ph.D.

Akihiro Tomoyasu received M.S. in Pharmaceutical Sciences from Hokkaido University. He joined Snow Brand Milk Industry Company, Limited. (currently MEGMILK SNOW BRAND Co.,Ltd.) and then joined Chugai Pharmaceutical Co., Ltd. After the work in life sciences industry, he was engaged in venture investment development business in UFJ Capital Co., Ltd. (currently Mitsubishi UFJ Capital Co., Ltd.). He is currently the external directors of KinoPharma, Inc., Kringle Pharma, Inc., and the director of Anicom Capital Co. Ltd. since 2016.

Takayuki Oda,
Attorney at Law

Takayuki Oda graduated from the Faculty of Law, Doshisha University.
He was engaged in corporate legal affairs, listing preparation (Mothers), M & A, etc. at a management consulting company and bio-venture company. After working at Tairaka Law Office, he opened Oda Law Office (currently Oda & Hoshino Law Office) in 2018. He is currently the director of Zero Storia Inc.